161 related articles for article (PubMed ID: 28846559)
1. Sofosbuvir-Based Regimens in HIV/HCV Coinfected Patients After Liver Transplantation: Results From the ANRS CO23 CUPILT Study.
Antonini TM; Coilly A; Rossignol E; Fougerou-Leurent C; Dumortier J; Leroy V; Veislinger A; Radenne S; Botta-Fridlund D; Durand F; Houssel-Debry P; Kamar N; Canva V; Perré P; De Ledinghen V; Rohel A; Diallo A; Taburet AM; Samuel D; Pageaux GP; Duclos-Vallée JC;
Transplantation; 2018 Jan; 102(1):119-126. PubMed ID: 28846559
[TBL] [Abstract][Full Text] [Related]
2. Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.
Grant JL; Hawkins C; Brooks H; Palella FJ; Koppe SW; Abecassis MM; Stosor V
AIDS; 2016 Jan; 30(1):93-8. PubMed ID: 26731756
[TBL] [Abstract][Full Text] [Related]
3. Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.
Campos-Varela I; Moreno A; Morbey A; Guaraldi G; Hasson H; Bhamidimarri KR; Castells L; Grewal P; Baños I; Bellot P; Brainard DM; McHutchison JG; Terrault NA
Aliment Pharmacol Ther; 2016 Jun; 43(12):1319-29. PubMed ID: 27098374
[TBL] [Abstract][Full Text] [Related]
4. Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.
Rockstroh JK; Ingiliz P; Petersen J; Peck-Radosavljevic M; Welzel TM; Van der Valk M; Zhao Y; Jimenez-Exposito MJ; Zeuzem S
Antivir Ther; 2017; 22(3):225-236. PubMed ID: 27845298
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment with sofosbuvir of fibrosing cholestatic hepatitis C after liver transplantation in an HIV-HCV-coinfected patient.
Borentain P; Colson P; Dhiver C; Gregoire E; Hardwigsen J; Botta-Fridlund D; Garcia S; Gerolami R
Antivir Ther; 2015; 20(3):353-6. PubMed ID: 25105441
[TBL] [Abstract][Full Text] [Related]
6. Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation.
Dumortier J; Leroy V; Duvoux C; de Ledinghen V; Francoz C; Houssel-Debry P; Radenne S; d'Alteroche L; Fougerou-Leurent C; Canva V; di Martino V; Conti F; Kamar N; Moreno C; Lebray P; Tran A; Besch C; Diallo A; Rohel A; Rossignol E; Abergel A; Botta-Fridlund D; Coilly A; Samuel D; Duclos-Vallée JC; Pageaux GP
Liver Transpl; 2016 Oct; 22(10):1367-78. PubMed ID: 27348086
[TBL] [Abstract][Full Text] [Related]
7. Sofosbuvir and daclatasvir in mono- and HIV-coinfected patients with recurrent hepatitis C after liver transplant.
Castells L; Llaneras J; Campos-Varela I; Bilbao I; Crespo M; Len O; Rodríguez-Frías F; Charco R; Salcedo T; Esteban JI; Esteban-Mur R
Ann Hepatol; 2017 Jan-Feb 2017; 16(1):86-93. PubMed ID: 28051797
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation.
Leroy V; Dumortier J; Coilly A; Sebagh M; Fougerou-Leurent C; Radenne S; Botta D; Durand F; Silvain C; Lebray P; Houssel-Debry P; Kamar N; D'Alteroche L; Petrov-Sanchez V; Diallo A; Pageaux GP; Duclos-Vallee JC;
Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1993-2001.e1-2. PubMed ID: 26044317
[TBL] [Abstract][Full Text] [Related]
9. 12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.
Luetkemeyer AF; McDonald C; Ramgopal M; Noviello S; Bhore R; Ackerman P
Clin Infect Dis; 2016 Jun; 62(12):1489-96. PubMed ID: 27025835
[TBL] [Abstract][Full Text] [Related]
10. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
Sogni P; Gilbert C; Lacombe K; Piroth L; Rosenthal E; Miailhes P; Gervais A; Esterle L; Chas J; Poizot-Martin I; Dominguez S; Simon A; Morlat P; Neau D; Zucman D; Bouchaud O; Lascoux-Combe C; Bani-Sadr F; Alric L; Goujard C; Vittecoq D; Billaud E; Aumaître H; Boué F; Valantin MA; Dabis F; Salmon D; Wittkop L
Clin Infect Dis; 2016 Sep; 63(6):763-770. PubMed ID: 27317796
[TBL] [Abstract][Full Text] [Related]
11. IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting.
Londoño MC; Manzardo C; Rimola A; Ruiz P; Costa J; Forner A; Ambrosioni J; Agüero F; Laguno M; Lligoña A; Moreno A; Miró JM
J Antimicrob Chemother; 2016 Nov; 71(11):3195-3201. PubMed ID: 27402009
[TBL] [Abstract][Full Text] [Related]
12. Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.
Grottenthaler JM; Werner CR; Steurer M; Spengler U; Berg T; Engelmann C; Wedemeyer H; von Hahn T; Stremmel W; Pathil A; Seybold U; Schott E; Blessin U; Sarrazin C; Welker MW; Harrer E; Scholten S; Hinterleitner C; Lauer UM; Malek NP; Berg CP
PLoS One; 2018; 13(6):e0197544. PubMed ID: 29874250
[TBL] [Abstract][Full Text] [Related]
13. Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection.
Liu CH; Sun HY; Liu CJ; Sheng WH; Hsieh SM; Lo YC; Liu WC; Su TH; Yang HC; Hong CM; Tseng TC; Chen PJ; Chen DS; Hung CC; Kao JH
Aliment Pharmacol Ther; 2018 Jun; 47(12):1690-1698. PubMed ID: 29665069
[TBL] [Abstract][Full Text] [Related]
14. Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy.
Donato MF; Morelli C; Romagnoli R; Invernizzi F; Mazzarelli C; Iemmolo RM; Montalbano M; Lenci I; Bhoori S; Pieri G; Berardi S; Caraceni P; Martini S;
Liver Int; 2017 May; 37(5):678-683. PubMed ID: 27865034
[TBL] [Abstract][Full Text] [Related]
15. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
Fontana RJ; Brown RS; Moreno-Zamora A; Prieto M; Joshi S; Londoño MC; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri SM; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR
Liver Transpl; 2016 Apr; 22(4):446-58. PubMed ID: 26890629
[TBL] [Abstract][Full Text] [Related]
16. Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study.
Coilly A; Fougerou-Leurent C; de Ledinghen V; Houssel-Debry P; Duvoux C; Di Martino V; Radenne S; Kamar N; D'Alteroche L; Leroy V; Canva V; Lebray P; Moreno C; Dumortier J; Silvain C; Besch C; Perre P; Botta-Fridlund D; Anty R; Francoz C; Abergel A; Debette-Gratien M; Conti F; Habersetzer F; Rohel A; Rossignol E; Danjou H; Roque-Afonso AM; Samuel D; Duclos-Vallée JC; Pageaux GP;
J Hepatol; 2016 Oct; 65(4):711-718. PubMed ID: 27262758
[TBL] [Abstract][Full Text] [Related]
17. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
[TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience.
Faisal N; Bilodeau M; Aljudaibi B; Hirsch G; Yoshida EM; Hussaini T; Ghali MP; Congly SE; Ma MM; Leonard J; Cooper C; Peltekian K; Renner EL; Lilly LB
Transplantation; 2016 May; 100(5):1059-65. PubMed ID: 26950722
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort.
Barrail-Tran A; Goldwirt L; Gelé T; Laforest C; Lavenu A; Danjou H; Radenne S; Leroy V; Houssel-Debry P; Duvoux C; Kamar N; De Ledinghen V; Canva V; Conti F; Durand F; D'Alteroche L; Botta-Fridlund D; Moreno C; Cagnot C; Samuel D; Fougerou-Leurent C; Pageaux GP; Duclos-Vallée JC; Taburet AM; Coilly A
Eur J Clin Pharmacol; 2019 Nov; 75(11):1555-1563. PubMed ID: 31384986
[TBL] [Abstract][Full Text] [Related]
20. Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection.
Bunnell KL; Vibhakar S; Glowacki RC; Gallagher MA; Osei AM; Huhn G
Pharmacotherapy; 2016 Sep; 36(9):e148-53. PubMed ID: 27459733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
